Literature DB >> 24568472

Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma.

Nan Wang1, Yin-Zhang Lv, An-Hui Xu, Yan-Rong Huang, Ling Peng, Jia-Rui Li.   

Abstract

OBJECTIVE: To explore the efficiency of single application of lobaplatin in tran-scatheter arterial chemoembolization (TACE) for patients with a primary hepatic carcinoma who were unable or unwilling to undergo surgery.
METHODS: 173 patients with primary hepatic carcinoma diagnosed by imaging or pathology were randomly divided into experimental and control groups and respectively treated with lobaplatin and pirarubicin hydrochloride as chemotherapeutic drugs for TACE. The amount of iodipin was regulated according to the tumor number and size, and then gelatin sponge or polyvinyl alcohol particles were applied for embolisms. The efficiency of treatment in the two groups was compared with reference to survival time and therapeutic response.
RESULTS: The experimental group (single lobaplatin as chemotherapy drug) was superior to control group (single pirarubicin hydrochloride as chemotherapy drug) in the aspects of survival time and therapeutic response, with statistical significance.
CONCLUSIONS: Single lobaplatin can be as a chemotherapy drug in TACE and has better efficiency in the aspects of mean survival time and therapeutic response, deserving to be popularized in the clinic.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24568472     DOI: 10.7314/apjcp.2014.15.2.647

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

2.  Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma.

Authors:  Yan Zheng; Yin Li; Xianben Liu; Haibo Sun; Guanghui Liang; Jiajia Hu; Liping Li; Wenqun Xing
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

3.  Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma.

Authors:  Yuanxun Yue; Zhizhong Ren; Ying Liu; Yuewei Zhang
Journal:  J Interv Med       Date:  2019-06-27

4.  A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.

Authors:  Xiujuan Wu; Peng Tang; Shifei Li; Shushu Wang; Yueyang Liang; Ling Zhong; Lin Ren; Ting Zhang; Yi Zhang
Journal:  Nat Commun       Date:  2018-02-26       Impact factor: 14.919

Review 5.  Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis.

Authors:  Tao Guo; Ping Wu; Pengpeng Liu; Baiyang Chen; Xiang Jiang; Yang Gu; Zhisu Liu; Zhen Li
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.